As of 2026-06-26, TransCode Therapeutics, Inc. Common Stock (RNAZ) has a 3-month relative strength percentile of 7 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 35. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 15.4%, relative volume 0.11×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RNAZ ranks at the 42th percentile over 1 month, 7th percentile over 3 months, 19th percentile over 6 months, 23th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
RNAZ is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
RNAZ currently shows a 20-day average daily range (ADR%) of 15.4%, a 90-day beta versus the S&P 500 of -0.16. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes RNAZ's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what RNAZ has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
RNAZ most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-15. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.
§ Seasonality
10y · since 2022
Best monthJanon averageavg +21.33% · 75% win · n 4
Worst monthMaron averageavg -30.88% · 0% win · n 4